Literature DB >> 25399712

Meaningful use of pharmacogenetics.

M J Ratain1, J A Johnson2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25399712     DOI： 10.1038/clpt.2014.188

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533

2.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

3.  Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education.

Authors:  Jasmine A Luzum; Matthew J Luzum
Journal:  Per Med       Date:  2016-03-01       Impact factor: 2.512

Review 4.  Evidence and resources to implement pharmacogenetic knowledge for precision medicine.

Authors:  Kelly E Caudle; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Mary V Relling; Teri E Klein
Journal:  Am J Health Syst Pharm       Date:  2016-12-01       Impact factor: 2.637

Review 5.  Moving Pharmacogenetics Into Practice: It's All About the Evidence!

Authors:  Jasmine A Luzum; Natasha Petry; Annette K Taylor; Sara L Van Driest; Henry M Dunnenberger; Larisa H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2021-07-07       Impact factor: 6.903

6.  Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.

Authors:  E C M Tonk; D Gurwitz; A-H Maitland-van der Zee; A C J W Janssens
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 7.  Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.

Authors:  Marleen E Jansen; T Rigter; W Rodenburg; T M C Fleur; E J F Houwink; M Weda; Martina C Cornel
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

8.  Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?

Authors:  Jasmine A Luzum; David E Lanfear
Journal:  J Am Heart Assoc       Date:  2016-03-28       Impact factor: 5.501

9.  Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources.

Authors:  Tyler Shugg; Amy L Pasternak; Bianca London; Jasmine A Luzum
Journal:  NPJ Genom Med       Date:  2020-10-30       Impact factor: 8.617
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.